Esperance Pharmaceuticals
Founded Year
2005Stage
Convertible Note | AliveTotal Raised
$22.7MLast Raised
$1M | 4 yrs agoMissing: Esperance Pharmaceuticals's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Esperance Pharmaceuticals's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Esperance Pharmaceuticals
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Esperance Pharmaceuticals is included in 2 Expert Collections, including Cancer.
Cancer
4,784 items
Pharmaceutical and biotechnology companies with cancer therapy drug candidates.
Biopharma Tech
15,535 items
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Esperance Pharmaceuticals Patents
Esperance Pharmaceuticals has filed 14 patents.
The 3 most popular patent topics include:
- Oncology
- Clusters of differentiation
- Experimental cancer drugs
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
10/8/2018 | 7/20/2021 | Molecular biology, G protein coupled receptors, Transcription factors, Olfactory receptors, Peptides | Grant |
Application Date | 10/8/2018 |
|---|---|
Grant Date | 7/20/2021 |
Title | |
Related Topics | Molecular biology, G protein coupled receptors, Transcription factors, Olfactory receptors, Peptides |
Status | Grant |
Latest Esperance Pharmaceuticals News
Dec 2, 2017
22:58 EST 1 Dec 2017 | BioPortfolio Reports Summary Esperance Pharmaceuticals Inc Esperance is a developer of oncology products. The company develops and distributes drugs for the treatment of cancer . Its products comprise EP100 peptide conjugate, EP200 peptide conjugate, EP300 peptide conjugates and antibody drug conjugates . Esperance develops drugs for the treatment of ovarian, breast, endometrial, prostate, pancreatic, solid tumors and blood cancers. The company uses cationic lytic peptide technology platform for the development of drugs. It develops targeted cancer therapeutics called membrane disrupting peptides to kills cancer cells. Esperance is headquartered in Houston, Texas, the US. Esperance Pharmaceuticals Inc Pharmaceuticals Healthcare Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, subsector and regions. GlobalData derived the data presented in this report from proprietary inhouse Pharma eTrack deals database, and primary and secondary research. Scope Financial Deals Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. Deals by Year Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. Deals by Region Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. Deals by Subsector Chart and table showing information on the number of deals and value reported by the company, by subsector. Major Deals Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios. Business Description A brief description of the company's operations. Key Employees A list of the key executives of the company. Important Locations and Subsidiaries A list and contact details of key centers of operation and subsidiaries of the company. Key Competitors A list of the key competitors of the company. Key Recent Developments A brief on recent news about the company. Reasons to Buy Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period. Understand the company's business segments' expansion / divestiture strategy The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy. Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios. Equip yourself with detailed information about the company's operations to identify potential customers and suppliers. The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors. Stay uptodate on the major developments affecting the company Recent developments concerning the company presented in the profile help you track important events. Gain key insights into the company for academic or business research Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs. Note*: Some sections may be missing if data is unavailable for the company. Related Biotechnology, Pharmaceutical and Healthcare News
Esperance Pharmaceuticals Frequently Asked Questions (FAQ)
When was Esperance Pharmaceuticals founded?
Esperance Pharmaceuticals was founded in 2005.
Where is Esperance Pharmaceuticals's headquarters?
Esperance Pharmaceuticals's headquarters is located at 909 Fannin St., Houston.
What is Esperance Pharmaceuticals's latest funding round?
Esperance Pharmaceuticals's latest funding round is Convertible Note.
How much did Esperance Pharmaceuticals raise?
Esperance Pharmaceuticals raised a total of $22.7M.
Who are the investors of Esperance Pharmaceuticals?
Investors of Esperance Pharmaceuticals include BVM Capital, Louisiana Funds, Research Corporation Technologies, Louisiana Technology Fund, Sanofi and 5 more.
Who are Esperance Pharmaceuticals's competitors?
Competitors of Esperance Pharmaceuticals include AVEO Oncology, ISA Pharmaceuticals, Stemina Biomarker Discovery, Histogen, OncoMed Pharmaceuticals, NellOne Therapeutics, Napo Pharmaceuticals, Selexys Pharmaceuticals, Activate Immunotherapy, Afferent Pharmaceuticals and 47 more.
Compare Esperance Pharmaceuticals to Competitors
Marillion Pharmaceuticals, Inc. - Marillion is developing clinical-stage drugs in oncology and oncology supportive care. 177Lu-AMBA is a targeted radiotherapeutic, with the low level radiation of lutetium that aims to utilize an receptor-based technology, and can serve as both a diagnostic and therapeutic agent. The targeting capability means that 177Lu-AMBA homes in on tumor cells and spares normal tissues. 177Lu-AMBA is being pursued initially to treat hormone-resistant prostate cancer, has been studied in a phase I trial in Europe. Marillion also is developing PilobucTM , buccal formulation of pilocarpine ,for the treatment of dry mouth, shown in clinical trials to effectively and conveniently deliver the drug with reduced side effects compared to other routes of administration.PilobucTM buccal formulation of pilocarpine has the potential to be a product in the xerostomia market. Marillion is preparing for phase II trials of the product candidate..
CoImmune, fka Argos Therapeutics, is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases. Using biological components from each patient, the company's immunotherapies employ the patient's dendritic cells to activate an immune response specific to the patient's disease.
Onyvax is developing new cancer therapies that harness the selective power of the immune system to seek out and destroy tumor cells. Onyvax's products specifically target cancer cells, increasing the likelihood that they will be effective while minimising side effects associated with many conventional treatments. These therapies can broadly be classed as therapeutic cancer vaccines. Onyvax's lead product is in clinical trials for the treatment of prostate cancer and is poised to enter the final stages of development. Onyvax is committed to the commercialisation of therapies that enhance survival while maintaining a high quality of life for patients. The Company is based in London and has collaborations with leading hospitals and other institutions throughout Europe and the US.
Stemina Cell Discovery discovers and validates small molecules as biomarkers for high-throughput drug screening and disease diagnostics using an all human system comprised of stem cells and the company's metabolomics platform. Metabolomics aims to enable the discovery of small molecules that can be used as candidate biomarkers of disease and pharmacological efficacy or toxicity. The human embryonic stem cell metabolome is a source of candidate biomarkers to predict, diagnose or measure the progress of disease or toxic response. Stemina aims to provide compound screening and diagnostic development for the pharmaceutical and biotechnology industries and academia under contract services or joint discovery agreements.
NovoCell, Inc./BresaGen is a stem cell engineering company dedicated to creating, delivering, and commercializing cell and drug therapies to treat diabetes and other chronic diseases. Novocell uses its cell encapsulation technology and expertise in cell implantation to develop a renewable source of specialized cells for the treatment of cellular diseases. Bresagen represents a division of Novocell's research operation.
Regenetech develops and offers intellectual property licenses in the area of Adult Stem Cell Expansion and therapeutic applications of adult stem cells. Regenetech uses a technology discovered by NASA in space experiments for growing three-dimensional (3D) stem cells in a weightless environment.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.